Iranian Scientists Present New Injectable Formulation of Risperidone Drug

‘Preparation of formulation and evaluation of injectable hydrogel system containing triblock PLGA-PEG-PLGA made by carbon dioxide supercritical fluid method and PLGA containing risperidone’ is the title of the research project of Farzin Hadizadeh, a professor of Mashhad University of Medical Sciences, which was completed with the support of the National Science Foundation of Iran.

“Schizophrenia is one of the severe brain problems that has affected more than 21 million people in the world. To control this disease, there are two categories of drugs, including old first generation drugs and new second generation drugs; the latter drugs have less side effects and are more tolerated by the patient,” said Hadizadeh.

Noting that resperidone is a second-generation drug that is used for various diseases like autism, hyperactivity, and bipolar disease, he said, “To reduce patient non-cooperation with oral consumption, slow-release dosage forms have been developed for several drugs controlling these disorders.”

“One of the advantages of these pharmaceutical forms is the reduction of acute symptoms compared to oral formulations. Also, the main advantage of the injectable slow-release system is that it maintains the drug in a therapeutic concentration for a long time; for instance, one month, and there is no need to take the drug repeatedly orally,” Hadizadeh said.

Risperidone is an antipsychotic medicine that works by changing the effects of chemicals in the brain.

Risperidone is used to treat schizophrenia in adults and children who are at least 13 years old.

Risperidone is also used to treat symptoms of bipolar disorder (manic depression) in adults and children who are at least 10 years old.

Risperidone is not approved for use in older adults with dementia-related psychosis.

4155/v